Inhibrx Biosciences, Inc. Share Price & Technical Analysis
INBX · $104.0 (+2.62%)
Healthcare / Biotechnology
$104.0
+2.62%
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-base…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 3 years shown)
-21% return in May, 24% avg return in past 3 year May month.
53% return in 2026, 142% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | -2% | -7% | 88% | -21% | – | – | – | – | – | – | – | 53% |
| 25 | -11% | 0% | 7% | -12% | 10% | 6% | 55% | 31% | 21% | 144% | 5% | -7% | 249% |
| 24 | – | – | – | – | 38% | -14% | 4% | 0% | 8% | 3% | -6% | 2% | 35% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.48B
P/E ratio
—
52W high
$155.3
52W low
$12.68
Volume
1,04,008
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Inhibrx Biosciences, Inc. share price today?
- Inhibrx Biosciences, Inc. (INBX) last traded around $104.0 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INBX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INBX. Download the app for real-time alerts.
- How can I analyze Inhibrx Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.